Jasper Therapeutics & Amplitude Healthcare Acquisition Corporation Merger
You are now leaving the Jasper Therapeutics, Inc. site to a 3rd party website. Jasper Therapeutics is not responsible for 3rd party website content.
Jasper is a biotechnology company focused on enabling cures with hematopoietic cell transplants. Our broad pipeline includes our lead compound, JSP191, a unique antibody in clinical development as a conditioning agent to clear stem cells from bone marrow in patients undergoing a hematopoietic cell transplant. We are also advancing a novel engineered hematopoietic stem cell (eHSC) platform to improve the safety and increase the cure rate of allogeneic and autologous gene therapy grafts. Our mission is to make safer and curative hematopoietic transplantation possible for more indications and available to all types of patients, including infants, children, the elderly and other fragile populations.
JSP191 is a first-in-class CD117 monoclonal antibody conditioning agent designed to enable safer and more effective curative hematopoietic cell transplants and gene therapies. The initial indication is severe combined immunodeficiency (SCID), for which we are currently conducting a Phase 1/2 study. We also are evaluating JSP191 in a Phase 1 study in patients with myelodysplastic syndrome (MDS) or acute myeloid leukemia (AML). Jasper has partnered with academia as well as industry to expand the application of JSP191 to sickle cell disease with the NIH, Fanconi anemia with Stanford University and X-linked SCID with Graphite Bio. Later this year, Jasper will initiate a pilot study to evaluate JSP191 in autoimmune disorders, including multiple sclerosis, systemic lupus erythematosus and severe scleroderma.
Jasper’s Engineered Hematopoietic Stem Cells (eHSCs) are designed to overcome key limitations of allogeneic and autologous gene-edited stem cell grafts. By using mRNA or DNA editing, Jasper can give the modified donor or autologous stem cells a proliferative and survival advantage (transient or permanent) over the patient’s existing stem cells.
Jasper Therapeutics’ management team is comprised of experienced biopharma industry veterans with extensive track records in drug development and commercialization. With this leadership, we are well positioned to achieve our vision of increasing cure rates of allogeneic and gene therapy grafts and significantly increasing the eligible patient population.
June 21, 2021
June 14, 2021
June 1, 2021
May 26, 2021
May 19, 2021
May 7, 2021
May 6, 2021
February 11, 2021
February 8, 2021
January 13, 2021